Bright Uro Inc. raised $23 million in a series A fundraising round to support its pursuit of U.S. FDA 510(k) clearance and launch of its Glean urodynamics system. Glean offers catheter-less assessment of the function of the bladder and urethra that uses an inserted pressure sensor instead.

Launching a company based on knowledge that “the fundamental principle that most people hold to be true is off by a trillion” is a rare opportunity, said Jake Rubens, co-founder and president of Quotient Therapeutics Inc., a company that emerged from stealth this week, backed by two years of platform development and a $50 million investment from Flagship Pioneering.

Cancer Research UK (CRUK) is worried that rising prices and its total dependence on public donations mean its funding model is becoming unsustainable. The charity is calling on the U.K. government to step in and plug a £1 billion (US$1.23 billion) shortfall it said will open up over the next decade, in order to maintain investment at 2019 levels in real terms.